Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tryp Therapeutics Inc (OP:TRYPF)

N/A UNCHANGED
Last Price Updated: 3:17 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tryp Therapeutics Inc

< Previous 1 2 3 4 5 Next >
BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Looking to Change Narrative in Treating Fibromyalgia, Chronic Pain
Via Investor Brand Network
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Updating Trial Protocols in Response to FDA Request as Tryp Prepares Synthetic Psilocybin Studies for Eating Disorder, Fibromyalgia Treatment
Via Investor Brand Network
Recent Sector News Reveals Positive Data in Psychedelic Treatments For Depression as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Nears Launch of Synthetic Psilocybin Trials
Via Investor Brand Network
BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leveraging Partnerships to Facilitate TRP-8803’s Advancement
Via Investor Brand Network
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
Detroit Decriminalizes Psychedelics 
Via Benzinga
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Marks Another Significant Milestone with IND Application for Fibromyalgia Phase 2a Clinical Trial
Via Investor Brand Network
BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Participate in Panel Discussion at Wonderland: Miami
Via Investor Brand Network
BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Submits IND Application to Evaluate Clinical Candidate in Phase 2a Trial in Fibromyalgia
Via Investor Brand Network
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Way Through Unique Psychedelic Drug Development Focus
Via Investor Brand Network
Topics Intellectual Property
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Transforming Treatment of Fibromyalgia and Chronic Pain Conditions
Via Investor Brand Network
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at Upcoming Pain Therapeutics Summit
Via Investor Brand Network
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announced Inclusion in AdvisorShares Psychedelics ETF; KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing
Via Investor Brand Network
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Clinical Hold on Planned Eating Disorder Phase 2a Study
Via Investor Brand Network
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with University of Wisconsin Researchers for Clinical Pharmacology Studies Evaluating TRP-8803
Via Investor Brand Network
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
The Week In Psychedelics 
Via Benzinga
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Included in AdvisorShares Psychedelics ETF
Via Investor Brand Network
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at KSCA Psychedelics Virtual Investor Conference
Via Investor Brand Network
BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Preparing for Clinical Trials Amid Growing Push for New Federally Approved Therapeutic
Via Investor Brand Network
Topics Cannabis
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Launch of New Website and Resources
Via Investor Brand Network
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Collaboration with University of Wisconsin Researchers to Evaluate TRP-8803
Via Investor Brand Network
NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Therapeutic Options to Diseases with Unmet Needs
Via Investor Brand Network
Topics Cannabis
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Achieves Most Important Milestone Yet with Submission of IND Application for Phase 2a Clinical Trial
Via Investor Brand Network
Psychedelics Called the ‘Next Frontier’ for Investors, Also Offer Promising Treatments
Via Investor Brand Network
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Working to Bring Psychedelic Treatments Closer to the People
Via Investor Brand Network
Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases
Via Investor Brand Network
Topics Cannabis
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Continues to Increase Awareness of Novel Psychedelic Drug Candidates
Via Investor Brand Network
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Submission of IND Application for Eating Disorders Clinical Trial
Via Investor Brand Network
Senate Bill Decriminalizing Psychedelics Could Help Reverse Some “War on Drugs” Impacts
Via FinancialNewsMedia
CORRECTION FROM SOURCE: Tryp Therapeutics to Present at H.C. Wainwright Global Investment Conference
A correction from Tryp Therapeutics Inc. is being issued for the news release disseminated earlier today. The correction relates to... 
Via Newsfile
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.